

## Press Release

Zug, 31 August 2011

### Closing of the sale of mtm laboratories to Roche

The sale of mtm laboratories to Roche was closed today. With the closing, HBM BioVentures received net proceeds of EUR 42 million. Additional funds up to EUR 4.7 million will be due upon release of escrow. Approx. EUR 20 million may be obtained upon reaching performance-related milestones. With its investment in mtm laboratories, HBM BioVentures realized an annualized return over the investment period of 19%. This trade sale in July 2011 doubled the book value of the investment position and increased the net asset value by 5.8%.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, Tel.: +41 41 768 11 08, [andreas.wicki@hbmbioventures.com](mailto:andreas.wicki@hbmbioventures.com).

#### About HBM BioVentures Ltd

HBM BioVentures is invested globally in some 25 mature companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many companies in HBM BioVentures' portfolio are either at an advanced stage of development or already available on the market. The investment focus currently is on follow-on financing for still-private companies in the portfolio that offer high value-creation potential. HBM BioVentures is an interesting alternative to investments in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

#### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.